|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500111791 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-05 18:04:12 |
|
注册时间: Date of Registration: |
2025-11-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
既往致残患者再发急性缺血性卒中接受血管内治疗的前瞻性、登记性队列(RESTORE) |
|
Public title: |
Prospective, Multicenter Registry of Patients with Previous Disability Receiving Endovascular Treatment Acute Ischemic Stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
既往致残患者再发急性缺血性卒中接受血管内治疗的前瞻性、登记性队列(RESTORE) |
|
Scientific title: |
Prospective, Multicenter Registry of Patients with Previous Disability Receiving Endovascular Treatment Acute Ischemic Stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
资文杰 |
研究负责人: |
资文杰 |
|
Applicant: |
Wenjie Zi |
Study leader: |
Wenjie Zi |
|
申请注册联系人电话: Applicant telephone: |
+86 18523033816 |
研究负责人电话: Study leader's telephone: |
+86 18523033816 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ziwenjie@126.com |
研究负责人电子邮件: Study leader's E-mail: |
ziwenjie@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区新桥正街183号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街83号 |
|
Applicant address: |
183 Xingiaozheng Street, Shapingba District, Chongging |
Study leader's address: |
183 Xingiaozheng Street, Shapingba District, Chongging |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军军医大学第二附属医院(新桥医院) |
||
|
Applicant's institution: |
Second Affiliated Hospital of Army Medical University (Xingiao Hospital) |
||
|
研究负责人所在单位: |
中国人民解放军陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of the Army Medical University PLA |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-研第186-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Second Affiliated Hospital of Army Medical University PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-31 00:00:00 |
||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Hu Lanlan |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥正街83号 |
||
|
Contact Address of the ethic committee: |
183 Xingiaozheng Street, Shapingba District, Chongging |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68755422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
35341579@qq.com |
|
研究实施负责(组长)单位: |
中国人民解放军陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of the Army Medical University PLA |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
183 Xingiaozheng Street, Shapingba District, Chongging |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金;陆军军医大学第二附属医院2022年度医院学科人才建设专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
The National Science Fund for Distinguished Young Scholars;2022 hospital discipline talent construction project of the Second Affiliated Hospital of TMMU |
||||||||||||||||||||||
|
Target disease: |
Acute ischemic stroke |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
开展多中心、前瞻性、登记性队列研究,使用真实世界数据探索既往致残患者血管内治疗的有效性和安全性,为制定既往致残患者个体化治疗方案提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Objective to carry out a multicenter, prospective, registered cohort study, and explore the effectiveness and safety of intravascular treatment for patients with previous disability using real-world data, so as to provide a scientific basis for the development of individualized treatment for patients with previous disability. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.急性前循环大中血管闭塞或后循环大血管闭塞患者(颈内动脉颅内段,大脑中动脉M1-M3段,大脑前动脉A1-A3段,椎动脉V4段,基底动脉以及大脑后动脉P1-P3段); 2.术前具有轻度及以上功能障碍(mRS≥2分)持续至少3个月; 3.患者或家属签署书面知情同意书; 4.18岁≤年龄≤120岁。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients with acute anterior circulation occlusion or posterior circulation occlusion (intracranial segment of internal carotid artery, M1-M3 segment of middle cerebral artery, A1-A3 segment of anterior cerebral artery, V4 segment of vertebral artery, P1-P3 segment of basilar artery and posterior cerebral artery); 2.Preoperative mild or above dysfunction (MRS>= 2) lasting for at least 3 months; 3.Written informed consent signed by patients or family members; 4.18 <= age <= 120. |
||||||||||||||||||||||
|
排除标准: |
1.妊娠或哺乳期妇女; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Pregnant or lactating women; 2.The symptoms and signs were aggravated after the first stroke, and the diagnosis was progressive stroke; 3.Intracranial hemorrhage confirmed by computed tomography (CT) or magnetic resonance imaging (MRI); 4.Researchers judged that the duration of disability before stroke was too short; 5.Expected failure to complete follow-up; 6.Midline displacement of brain due to cerebral hernia; 7.Other clinical trials currently involved will affect the results of this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-10-15 00:00:00至 To 2030-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-11-15 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在合理的要求下从研究负责人处获得 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Obtain from the research leader with reasonable request |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过CRF表进行数据记录和收集,EDC系统进行数据录入和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data is recorded and collected through CRF forms, while the EDC system is used for data entry and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |